Tag: #pfizer

Pfizer Raises 2026 Revenue Midpoint as Non-COVID Drugs Offset Pandemic Drag

Pfizer lifted the midpoint of its 2026 revenue forecast after stronger-than-expected sales from non-COVID drugs, despite a GAAP loss from write-downs.

$PFE, #pfizer, #pharmaceuticals, #earnings, #covid

Pfizer says Phase 3 LITFULO trials met key vitiligo endpoints; plans global regulatory filings

Pfizer said Phase 3 trials of LITFULO (ritlecitinib) met key endpoints in nonsegmental vitiligo across 2,174 patients, and it plans global regulatory filings.

$PFE, #pfizer, #vitiligo, #ritlecitinib

EU Authorizes Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for Ages 6 Months and Up

EU clears Pfizer and BioNTech’s 2026–27 XFG-adapted COVID-19 vaccine for people 6 months and older ahead of the 2026–27 respiratory season.

#covid19, #vaccine, #pfizer, #biontech, #xfg

Pfizer’s Phase 3 Lung Cancer Drug Misses Overall Survival Goal; Stronger Trend in Second‑Line Patients

Pfizer's Phase 3 lung cancer trial of sigvotatug vedotin missed its overall survival goal; company sees a stronger trend in second‑line patients.

$PFE, #pfizer, #oncology, #lungcancer, #clinicaltrials

Pfizer’s BRAFTOVI Combo Shows Longer Progression-Free Survival in First-Line BRAF V600E Metastatic Colorectal Cancer

Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.

$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi

Pfizer Keeps 2026 Outlook as Q1 Revenue Rises 5%; COVID Sales Slide

Pfizer posted 5% revenue growth in Q1 and kept its 2026 outlook, as gains from newer drugs offset steep declines in Comirnaty and Paxlovid sales.

$PFE, #pfizer, #earnings, #pharma